文献速递中医内科中药与中成药合理使用

补肺解毒颗粒治疗耐多药肺结核的多中心双盲随机对照试验

Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial.
PubMed 文献 · Chin J Integr Med · 2024-05-11

该多中心双盲随机对照试验纳入312例耐多药肺结核患者,在18个月长程化疗基础上加用补肺解毒颗粒或安慰剂。结果显示补肺解毒颗粒使治愈率提高13.6%(58.4% vs 44.8%,P=0.02),加速痰培养转阴,提高空洞闭合率并改善生活质量。

要点

  • 补肺解毒颗粒辅助长程化疗可提高耐多药肺结核治愈率13.6%。
  • 补肺解毒颗粒加速痰培养转阴(中位5个月 vs 11个月)。
  • 补肺解毒颗粒提高空洞闭合率并改善生活质量,安全性需监测。

核心结论

  • 在长程化疗方案基础上加用补肺解毒颗粒可显著提高耐多药肺结核患者的治愈率和空洞闭合率,并快速改善生活质量。

研究设计与样本

  • 多中心、双盲、随机对照试验,2012年12月至2016年12月在中国18家哨点医院开展,共纳入312例耐多药肺结核患者,按1:1分层随机分为补肺解毒颗粒组或安慰剂组。

主要发现

  • 完成试验216例(补肺解毒颗粒组111例,安慰剂组105例);补肺解毒颗粒组治愈率58.4%,安慰剂组44.8%,提高13.6%(P=0.02)。
  • 补肺解毒颗粒组痰培养转阴中位时间5个月,安慰剂组11个月。
  • 完成治疗患者中,补肺解毒颗粒组空洞闭合率50.6%(43/85),安慰剂组32.1%(26/81),P=0.02。
  • 强化治疗结束时,补肺解毒颗粒组在生理功能、总体健康、活力方面较安慰剂组显著改善(均P<0.01)。
  • 两组死亡率无显著差异:补肺解毒颗粒组5.1%(8/156),安慰剂组2.6%(4/156)。

关键数值与推荐

  • 两组均接受18个月长程化疗方案(6 Am-Lfx-P-Z-Pto,12 Lfx-P-Z-Pto),并分别每日两次服用补肺解毒颗粒或安慰剂,共18个月。
  • 主要结局为治愈率;次要结局包括痰培养转阴时间、肺空洞变化和生活质量。

临床怎么用

  • 对于耐多药肺结核患者,可考虑在长程化疗基础上联用补肺解毒颗粒作为辅助治疗,以提高治愈率、加速痰菌转阴并改善生活质量。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of Bufei Jiedu (BFJD) ranules as adjuvant therapy for patients with multidrug-resistant pulmonary tuberculosis (MDR-PTB). METHODS: A large-scale, multi-center, double-blinded, and randomized controlled trial was conducted in 18 sentinel hospitals in China from December 2012 to December 2016. A total of 312 MDR-PTB patients were randomly assigned to BFJD Granules or placebo groups (1:1) using a stratified randomization method, which both received the long-course chemotherapy regimen for 18 months (6 Am-Lfx-P-Z-Pto, 12 Lfx-P-Z-Pto). Meanwhile, patients in both groups also received BFJD Granules or placebo twice a day for a total of 18 months, respectively. The primary outcome was cure rate. The secondary outcomes included time to sputum-culture conversion, changes in lung cavities and quality of life (QoL) of patients. Adverse reactions were monitored during and after the trial. RESULTS: A total of 216 cases completed the trial, 111 in the BFJD Granules group and 105 in the placebo group. BFJD Granules, as an adjuvant treatment, increased the cure rate by 13.6% at the end of treatment, compared with the placebo (58.4% vs. 44.8%, P=0.02), and accelerated the median time to sputum-culture conversion (5 months vs. 11 months). The cavity closure rate of the BFJD Granules group (50.6%, 43/85) was higher than that of the placebo group (32.1%, 26/81; P=0.02) in patients who completed the treatment. At the end of the intensive treatment, according to the 36-item Short Form, the BFJD Granules significantly improved physical functioning, general health, and vitality of patients relative to the placebo group (all P<0.01). Overall, the death rates in the two groups were not significantly different; 5.1% (8/156) in the BFJD Granules group and 2.6% (4/156) in the placebo group. CONCLUSIONS: Supplementing BFJD Granules with the long-course chemotherapy regimen significantly increased the cure rate and cavity closure rates, and rapidly improved QoL of patients with MDR-PTB (Registration No. ChiCTR-TRC-12002850).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Zhang SY, Qiu L, Zhang SX, et al. Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial. Chin J Integr Med. 2024. PMID: 38733454. doi:10.1007/s11655-024-3812-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。